Inhalable Mucus-Penetrating Engineered Hybrid Nanomedicine for Enhanced Treatment of Idiopathic Pulmonary Fibrosis
Nano Letters · 06.08.2025 · 25 (31) · 11929-11939
DOI: 10.1021/acs.nanolett.5c02481 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, online erschienen am 14.07.2025. Verfasst von Jinglin Zou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Low-Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontier Science Center of the Materials…. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Mucus, Nanomedicine, Pyridones. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Sailing Program.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a life-threatening interstitial lung disease and is one of the complications observed in individuals following COVID-19 infection. Although inhalable nanomedicines hold promise, nebulization-induced shear stress, dense airway mucus barrier, and inefficient in vivo clearance substantially compromise nanomedicine delivery efficiency and biosafety, thereby limiting their therapeutic efficacies. Herein, an inhalable microenvironment-responsive hybrid nanomedicine (PFD@FPNs-CAT) encapsulated with pirfenidone (PFD) and modified with catalase (CAT) is developed, which is able to overcome the supramolecular interactions owing to the small particle size, electronegativity, and PEGylated surface, thus enhancing the accumulation of PFD@FPNs-CAT in the lesions. Moreover, the surface-anchored CAT is demonstrated to relieve hypoxia, thus reversing the immunosuppressive microenvironment and further enhancing the therapeutic efficacy against IPF. Notably, due to the relatively low quantity of silica doping, PFD@FPNs-CAT demonstrates high stability and excellent biocompatibility. This inhalable mucus-penetrating nanomedicine remarkably inhibits the progression of IPF, illuminating the bright prospects for IPF therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lab of Low-Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontier Science Center of the Materials Biology and Dynamic Chemistry, Shanghai Engineering Research Center o…
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200092, China.
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
ORCID-Profile: Xinlin Jia, Dapeng Zhang, Yongsheng Li
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Sailing Program
- Science and Technology Commission of Shanghai Municipality
- Shanghai Municipality
Zitieren
APA
Zou, J., Jiang, C., Zhang, J., Wan, S., Yang, Y., Leng, Y., Wang, S., Jia, X., Mao, Y., Zhang, D., & Li, Y. (2025). Inhalable Mucus-Penetrating Engineered Hybrid Nanomedicine for Enhanced Treatment of Idiopathic Pulmonary Fibrosis. Nano Letters, 25(31), 11929-11939. https://doi.org/10.1021/acs.nanolett.5c02481
Vancouver
Zou J, Jiang C, Zhang J, Wan S, Yang Y, Leng Y, et al. Inhalable Mucus-Penetrating Engineered Hybrid Nanomedicine for Enhanced Treatment of Idiopathic Pulmonary Fibrosis. Nano Letters. 2025;25(31):11929-11939. doi:10.1021/acs.nanolett.5c02481
BibTeX
@article{Zou2025,
author = {Zou, Jinglin and Jiang, Cong and Zhang, Jing and Wan, Shiyue and Yang, Yuzi and Leng, Yuheng and Wang, Shuqi and Jia, Xinlin and Mao, Yuanqing and Zhang, Dapeng and Li, Yongsheng},
title = {Inhalable Mucus-Penetrating Engineered Hybrid Nanomedicine for Enhanced Treatment of Idiopathic Pulmonary Fibrosis},
journal = {Nano Letters},
year = {2025},
volume = {25},
number = {31},
pages = {11929--11939},
doi = {10.1021/acs.nanolett.5c02481}
}
EUVIMED